STI-4398 / Sorrento - LARVOL DELTA

Sorrento to Host a R&D Day to Showcase COVID-19 Product Pipeline (GlobeNewswire) - "Sorrento Therapeutics, Inc....announced it will host a R&D Day conference call and simultaneous webcast on October 13th, 2020 focusing on its comprehensive multi-modal approach to COVID-19. R&D Day Agenda: Clinical Stage Products (cleared Phase 1 or Phase 2): STI-1499 (COVI-GUARDTM neutralizing antibody (nAb) against SARS-CoV-2 and its D614G Variant); STI-5656 (Abivertinib for reducing cytokine storm and associated ARDS: acute respiratory distress syndrome); Pre-Clinical Stage Products of high interest: STI-2020; COVI-SHIELDTM; STI-2030; STI-4398; STI-3333; STI-2099."

Clinical • Cytokine storm • Live event • Preclinical • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease

Brief-Sorrento Therapeutics received STI-4398 trial guidance from FDA for potential treatment of infected patients & as prophylactic for Covid-19 (Reuters) - "SORRENTO THERAPEUTICS - RECEIVED STI-4398 TRIAL GUIDANCE FROM FDA FOR POTENTIAL TREATMENT OF INFECTED PATIENTS & AS PROPHYLACTIC FOR COVID-19"

New P1 trial • Infectious Disease • Novel Coronavirus Disease

"Sorrento Develops STI-4398 (COVIDTRAP Protein) to Prevent and Treat COVID-19 https://t.co/3FZaAkYWlZ" (@Pharmashot)